526P Pharmacodynamic evidence for WEE1 target engagement in surrogate and tumor tissues from a phase I study of the WEE1 inhibitor ZN-c3
Pavani Chalasani(University of Arizona), Fernando Doñate(Unknown), Hirva Mamdani(Wayne State University), Mihaela Gazdoiu(Novartis (Switzerland)), Ahmed A. Samatar(Merck & Co., Inc., Rahway, NJ, USA (United States)), Marina G. Sergeeva(Friedrich-Alexander-Universität Erlangen-Nürnberg), Petrus R. de Jong(Discovery Institute), Anthony W. Tolcher(South Texas Accelerated Research Therapeutics), Philippe Pultar(Department of Pharmaceuticals), Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Milainy Rocha Viana, D. Voliotis(Bayer (United States)), Kenna Anderes(Mirati Therapeutics (United States))
Cited by 1
Related Papers
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
|Journal of Clinical Oncology|2023|882
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
|The Lancet Oncology|2019|564
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma
|New England Journal of Medicine|2023|530